发明公开
EP3269717A1 POLYMORPHIC AND PSEUDOPOLYMORPHIC FORMS OF PHARMACEUTICAL COMPOUND NXL104
审中-公开
药物化合物NXL104的多晶型和拟似形态
- 专利标题： POLYMORPHIC AND PSEUDOPOLYMORPHIC FORMS OF PHARMACEUTICAL COMPOUND NXL104
- 专利标题（中）： 药物化合物NXL104的多晶型和拟似形态
-
申请号： EP17182561.5申请日： 2010-10-08
-
公开(公告)号： EP3269717A1公开(公告)日： 2018-01-17
- 发明人: BHATTACHARYA, Sisir , BONNET, Alain , DEDHIYA, Mahendra G. , DUCANDAS, Véronique , GIULIANI, Alexandre , PRIOUR, Alain , RAVAUX, Valérie , SPARGO, Peter
- 申请人： PFIZER IRELAND PHARMACEUTICALS
- 申请人地址： Operations Support Group Ringaskiddy Cork IE
- 专利权人： PFIZER IRELAND PHARMACEUTICALS
- 当前专利权人： PFIZER IRELAND PHARMACEUTICALS
- 当前专利权人地址： Operations Support Group Ringaskiddy Cork IE
- 代理机构： Pfizer
- 优先权： FR0904864 20091009; US263663P 20091123
- 主分类号： C07D471/08
- IPC分类号： C07D471/08 ; A61K31/439 ; A61K31/551 ; A61P31/04
摘要：
The invention relates to the sodium salt of (1R,2S,5R)-7-oxo-6-sulfooxy-1,6-diazabicyclo[3.2.1]octane-2-carboxamide of formula (I)
in crystallised polymorphic form "B". The compound of the invention can be used as a medicament, in particular as a beta-lactamase inhibitor.
in crystallised polymorphic form "B". The compound of the invention can be used as a medicament, in particular as a beta-lactamase inhibitor.
公开/授权文献
信息查询
